Horizontal Tabs

Treatment Modalities 
Small Molecules
Medical Devices
Facilities/Translational Research 
Phase 1 Capability
  • Phase 1 population: ∼2 million over geographically large region
  • First-in-Man studies
  • Multi-centre Phase 1 studies
  • Mechanisms studied: Taxanes, TKI inhibitors, CDK inhibitors, aurora kinase inhibitors, TRAIL receptor antibodies, novel cytotoxic agents, novel packaging of existing agents
  • Centre specific translational research interest: DNA repair inhibitors, pre-clinical and early clinical development of small molecule inhibitors
Technology/equipment available within the centre
  • Magnetic resonance imaging and spectroscopy (MRI/S)
  • Positron emission tomography (PET) technology
  • GCLP compliant pharmacology and pharmacodynamic assessment laboratories

Other Facilities:

  • Dedicated cancer research scientific institute (Northern Institute for Cancer Research in the Paul O'Gorman Building)
  • Dedicated academic clinical trials unit in custom-built cancer centre for performing early clinical work
Sample collection

Tissue Banking: in-house HTA-compliant tumour bank, Northern Gynaecological cancer network tumour bank, other national banks for specific projects when required.

Centre contact responsible for sample collection: Melanie Griffin (email:

ECMC funding provides infrastructure support for early phase and translational research.  From the ECMC Newcastle portfolio, the following trials have been carried out.

Trial activity between 2012-2015:



Trial by disease type between 2012-2015: